LXEO Form 3: CFO Tamayo Files Initial Ownership Statement Showing No Shares
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Lexeo Therapeutics reported an initial Section 16 Form 3 for Louis Edward Tamayo, who is identified as Chief Financial Officer and an officer/director of the company. The form, with an event date of 08/15/2025, shows no securities beneficially owned by the reporting person at the time of filing. The filing was signed by an attorney-in-fact on 08/27/2025.
Positive
- Form 3 filed to disclose initial officer reporting status
- Reporting person identified as Chief Financial Officer (Louis Edward Tamayo)
Negative
- No securities beneficially owned reported on initial Form 3
- Potential lack of equity alignment between CFO and shareholders at filing date
FAQ
What did Lexeo Therapeutics' (LXEO) Form 3 filed by the CFO report?
The Form 3 for Louis Edward Tamayo reported no securities beneficially owned and identified him as Chief Financial Officer; the event date is 08/15/2025.
When was the event date and signature date on the LXEO Form 3?
The event requiring the statement is dated 08/15/2025 and the form shows a signature by an attorney-in-fact dated 08/27/2025.
Does the Form 3 show any derivative or equity holdings for LXEO CFO Tamayo?
No. The filing explicitly states no securities are beneficially owned; both non-derivative and derivative sections list no holdings.
What is the reporting relationship of Louis Edward Tamayo to Lexeo (LXEO)?
The form indicates the reporting person is a company Officer with the title Chief Financial Officer and is also marked as a Director.
Was the Form 3 filed jointly or by a single reporting person?
The filing indicates it was filed by one reporting person (single filer).